2013Clinical Infectious DiseasesOpen access

High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy

Ravindra K. Gupta, Ruth Goodall, Michael Rañopa, Cissy Kityo, Paula Munderi, Fred Lyagoba, Lincoln Mugarura, Charles F. Gilks, Pontiano Kaleebu, Deenan Pillay, for the DART Virology Group and Trial Team, Heiner Grosskurth, Paula Munderi, Geoffrey Kabuye, D. Nsibambi, Ronnie Kasirye, E. Zalwango, M. Nakazibwe, Bernard Kikaire, G. Nassuna, R. Massa, K. Fadhiru, M. Namyalo, Aisha Zalwango, L. Generous, P. Khauka, N. Rutikarayo, W. Nakahima, Apollo Mugisha, Jim Todd, Jonathan Levin, Sylvia Kiwuwa Muyingo, Anthony Ruberantwari, Pontiano Kaleebu, David Yirrell, N. Ndembi, Fred Lyagoba, Peter J. Hughes, M. Aber, A. Medina Lara, Scott A. Foster, Jovita Amurwon, Peter Mugyenyi, Cissy Kityo, Francis Ssali, D. Tumukunde, T. Otim, Joseph Kabanda, Hellen Musana, Juliet Akao, Hope Kyomugisha, Adolf Byamukama, J. Sabiiti, J. Komugyena, Priscilla Wavamunno, S. Mukiibi, Amos Drasiku, R Byaruhanga, O. Labeja, Pauline Katundu, S. Tugume, P. Awio, A. Namazzi, T. G. Bakeinyaga, H. Katabira, D. Abaine, J Tukamushaba, W. Anywar, W. Ojiambo, E. Angweng, Susan Murungi, W. Haguma, S. Atwiine, J. Kigozi, Ahmed Latif, J. Hakim, Val J. Robertson, Andrew Reid, Ennie Chidziva, R. Bulaya-Tembo, Godfrey Musoro, Fabian Taziwa, Cleophas Chimbetete, L. Chakonza, A. Mawora, C. Muvirimi, G Tinago, P. Svovanapasis, M. Simango, O. Chirema, J. Machingura, S Mutsai, Mwelwa Phiri, T Bafana, M. Chirara, L. Muchabaiwa, M. Muzambi, Elly Katabira, Allan Ronald, A. Kambungu, Fred Lutwama, A. Nanfuka, J Walusimbi, Evelyn Nabankema, R. Nalumenya, T. Namuli, R. Kulume, I. Namata, L. Nyachwo, A. Florence, A. Kusiima, E Lubwama, R. Nairuba, F. Oketta, E Buluma, R. Waita, Henry Ojiambo, F. Sadik, J Wanyama, P. Nabongo, Robert Ochai, D. Muhweezi, Charles F. Gilks, K. Boocock, C. Puddephatt, D. Winogron, J. Kyle Bohannon, J. Darbyshire, M. D. Gibb, Andy Burke, D. Bray, AG Babiker, Sarah Walker, H Wilkes, Mary Rauchenberger, S. Sheehan, Leon Peto, Kirk A. Taylor, Moira Spyer, Alexander Ferrier, B. Naidoo, David Dunn, R. Goodall, R. Nanfuka, C. Mufuka-Kapuya, Pontiano Kaleebu, Deenan Pillay, P. Awio, M. Chirara, David Dunn, C. Gilks, R. Goodall, Anne Kapaata, M. Katuramur, Fred Lyagoba, Rose Magala, Brian Magambo, K. Mataruka, Adele McCormick, Lincoln Mugarura, T. Musunga, M. Nabankkema, Jonathan Nkalubo, Peter Nkurunziza, Chris M. Parry, Val J. Robertson, Moira Spyer, David Yirrell, A. Medina Lara, Scott A. Foster, Jovita Amurwon, B. Nyanzi Wakholi, J. Kigozi, L. Muchabaiwa, M. Muzambi, Ian Weller, AG Babiker, Silver Bahendeka, Mary T. Bassett, A. Chogo Wapakhabulo, J. Darbyshire, B Gazzard, C. Gilks, J. Hakim, Ahmed Latif, C. Mapuchere, Owen Mugurungi, Peter Mugyenyi, Corey Burke, Samuel Adeniyi Jones, C.J. Newland, S Rahim, James F. Rooney, M. Kumi Smith, Wendy Snowden, J.-M. Steens, AM Breckenridge, Anya T. McLaren, C. Hill, Jonathan Matenga, Anton Pozniak, David Serwadda, Tim Peto, Adrian Palfreeman, Margaret Borok

Open full text 38 citations

Abstract

In a randomized comparison of nevirapine or abacavir with zidovudine plus lamivudine, routine viral load monitoring was not performed, yet 27% of individuals with viral failure at week 48 experienced resuppression by week 96 without switching. This supports World Health Organization recommendations that suspected viral failure should trigger adherence counseling and repeat measurement before a treatment switch is considered.

Open-access reader

About this research paper

What this paper is about

In a randomized comparison of nevirapine or abacavir with zidovudine plus lamivudine, routine viral load monitoring was not performed, yet 27% of individuals with viral failure at week 48 experienced resuppression by week 96 without switching. This supports World Health Organization recommendations that suspected viral failure should trigger adherence counseling and repeat measurement before a treatment switch is considered.

Why it matters

OpenAlex reports 38 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In a randomized comparison of nevirapine or abacavir with zidovudine plus lamivudine, routine viral load monitoring was not performed, yet 27% of individuals with viral failure at week 48 experienced resuppression by week 96 without switching. This supports World Health Organization recommendations that suspected viral failure should trigger adherence counseling and repeat measurement before a treatment switch is considered.

Key concepts: Medicine, Zidovudine, Nevirapine, Lamivudine, Abacavir, Viral load, Antiretroviral therapy, Second-line therapy

Related papers

Back to paper searchBrowse research topicsOriginal source
High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy — Research Paper | ScholarLens